Prince Pharmaceutical Co., Ltd. (TPEX:6935)
Taiwan · Delayed Price · Currency is TWD 28.70
-0.80 (-2.71%)
May 29, 2026, 12:00 PM CST
Prince Pharmaceutical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 96.32 | -53.54 | 15.31 | 51.55 | -8.3 |
Depreciation & Amortization | 61.61 | 62.49 | 58.56 | 52.35 | 45.34 |
Other Amortization | - | - | - | - | 0.88 |
Loss (Gain) From Sale of Assets | 0.17 | 0.14 | -0.06 | -0.06 | -0.09 |
Stock-Based Compensation | 0.91 | 9.32 | 6.27 | 2.93 | - |
Provision & Write-off of Bad Debts | 0.01 | - | -0.1 | 0.08 | 0.02 |
Other Operating Activities | 8.33 | -3.01 | 3.74 | 12.65 | -0.03 |
Change in Accounts Receivable | -69.62 | -8.44 | -32.4 | -3.72 | -14.86 |
Change in Inventory | -64.09 | 0.65 | 7.74 | -24.42 | -32.09 |
Change in Accounts Payable | 46.96 | 23.23 | 29.47 | -13.09 | 29 |
Change in Unearned Revenue | -1.15 | 2.83 | -12.17 | 3.87 | - |
Change in Other Net Operating Assets | 10.6 | 12.55 | -13.87 | 9.51 | 22.49 |
Operating Cash Flow | 90.06 | 46.21 | 62.5 | 91.65 | 42.36 |
Operating Cash Flow Growth | 94.89% | -26.07% | -31.81% | 116.38% | - |
Capital Expenditures | -18.24 | -18 | -62.05 | -19.53 | -40.98 |
Sale of Property, Plant & Equipment | 0.07 | 1.14 | 0.06 | 0.06 | 0.12 |
Sale (Purchase) of Intangibles | -0.56 | - | -0.19 | -0.28 | -0.3 |
Other Investing Activities | -0.8 | -0.46 | -5.82 | -20.27 | 2.36 |
Investing Cash Flow | -19.54 | -17.32 | -68.01 | -40.02 | -38.79 |
Long-Term Debt Issued | - | - | - | - | 68.45 |
Short-Term Debt Repaid | - | - | - | -30 | -45 |
Long-Term Debt Repaid | -40.51 | -39.5 | -38.7 | -22.17 | -11.59 |
Total Debt Repaid | -40.51 | -39.5 | -38.7 | -52.17 | -56.59 |
Net Debt Issued (Repaid) | -40.51 | -39.5 | -38.7 | -52.17 | 11.86 |
Issuance of Common Stock | 19.8 | - | 100.24 | - | - |
Common Dividends Paid | - | -9.15 | -5.43 | - | - |
Financing Cash Flow | -20.7 | -48.65 | 56.11 | -52.17 | 11.86 |
Net Cash Flow | 49.81 | -19.76 | 50.61 | -0.54 | 15.42 |
Free Cash Flow | 71.81 | 28.21 | 0.45 | 72.13 | 1.38 |
Free Cash Flow Growth | 154.56% | 6197.10% | -99.38% | 5118.96% | - |
Free Cash Flow Margin | 6.80% | 4.09% | 0.06% | 10.12% | 0.31% |
Free Cash Flow Per Share | 1.94 | 0.77 | 0.01 | 2.16 | 0.04 |
Cash Interest Paid | 9.59 | 10.27 | 10.46 | 8.92 | 5.59 |
Cash Income Tax Paid | 0.09 | 4.46 | 0.11 | 0.02 | -0.01 |
Levered Free Cash Flow | 38.61 | 42.18 | -3.52 | 46.01 | 4.07 |
Unlevered Free Cash Flow | 44.6 | 48.59 | 3.02 | 51.6 | 8.79 |
Change in Working Capital | -77.3 | 30.81 | -21.22 | -27.85 | 4.54 |